Argatroban · Regulatory label update

FDA supplemental approval: Argatroban (Labeling)

U.S. Food and Drug Administration · July 31, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental labeling change for argatroban (Accord Healthcare) on 31 July 2026. This regulatory record documents the approval action but does not contain clinical trial results, efficacy data, or safety evidence.

What was studied

Regulatory label update.

Key findings

Safety

This record does not contain clinical trial results, efficacy data, or safety data.

Who this may help

This record indicates a labeling update for argatroban but does not convey what clinical evidence or safety signal prompted the change. Clinicians should consult the updated prescribing information directly.

Plain-language summary

This is an FDA supplemental approval for labeling changes to argatroban; it documents a regulatory action but does not contain clinical trial data or efficacy evidence.

Clinical bottom line

Caveats

This record does not contain clinical trial results, efficacy data, or safety data.
The specific nature of the labeling change is not stated in this regulatory record.
No comparator, control arm, or outcome metrics are reported.
Background clinical evidence supporting the labeling change is not included in this document.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

This is a regulatory record, not a clinical study.

Directness

insufficient

Labeling action does not report clinical outcomes or comparative data.

Consistency

insufficient

No clinical evidence base reported in this regulatory record.

Risk of bias

insufficient

Not applicable to a labeling approval document.

Sample adequacy

insufficient

No study population or sample size reported.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA212035. This is a regulatory action record, not a clinical study. Brand name: ARGATROBAN. Active ingredient: ARGATROBAN. Sponsor: ACCORD HLTHCARE. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-31. Products: ARGATROBAN IN SODIUM CHLORIDE, SOLUTION, INTRAVENOUS, ARGATROBAN 50MG/50ML (1MG/ML).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Accord HlthcareArgatroban